At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VI...(addressingmemory function comes with the...),Health

Date:4/15/2008

addressing memory function comes with the scientific background for safety and indications of effectiveness that VIVIMIND(TM) can claim," stated Mr. Gary Schmid, newly appointed President and Chief Executive Officer of OVOS Natural Health Inc. "VIVIMIND(TM) is in a class by itself and we plan to make it the leader in the fast growing baby boomer, or zoomer, market where a key concern is to maintain health and delay the effects of aging," he added.

VIVIMIND(TM) will be made available to consumers through traditional retail channels, such as drug stores, mass merchandisers and grocery chains, as well as through leading health food stores. OVOS Natural Health is working towards the launch of a major advertising and information campaign for consumers.

New Pharmaceutical Development Pipeline

As previously announced, Neurochem will initiate a second Phase III clinical trial for eprodisate (KIACTA(TM)) in close cooperation with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA). This investigational product candidate is being developed for the treatment of a rare but devastating disease, Amyloid A (AA) amyloidosis, which attacks the kidney function and often leads to death.

The trial is expected to begin in the fourth quarter of 2008. It will be an international, double-blind, randomized, placebo-controlled and parallel design study of approximately 150 patients to be followed for a period of 24 months.

NC-503 is being studied for the treatment of Type II diabetes and certain features of metabolic syndrome. Results from animal studies using a rat model of diabetes and metabolic syndrome have shown that NC-503 protects the kidney and decreases the glycemic levels in obese diabetic, so-called Zucker rats, when compared to the control group. Treatment with NC-503 correlated with the preservation of 40% more cells secreting insulin than in the control group.

This program has now advanced into a Phase
'/>"/>

SOURCE NEUROCHEM INC. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. Otter Tail Corporation Holds 2008 Annual Meeting: Shareholders Elect Directors; Board Declares Quarterly Dividend
2. Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
3. Northwest Hospital & Medical Center Hosts Health & Wellness Pavilion At Second Annual King 5 Healthy Living Expo
4. European Society of Human Reproduction & Embryology 24th annual meeting
5. Media advisory - Neurochems Annual and Special Meeting of Shareholders April 15, 2008
6. Neurochem Annual and Special Meeting of shareholders
7. With annual deaths from malaria on the rise: Scientists ask where is all the money going?
8. China Medical Technologies to Announce 4QFY2007 Financial Results, Declare Annual Cash Dividend and Provide FY2008 Annual Targets on June 12, 2008
9. HealthMEDX Hosts Annual User Group Conference
10. Abaxis to Present at the SunTrust Robinson Humphreys 37th Annual Institutional Unconference
11. Access Pharmaceuticals to Present New Data on ProLindac(TM) at the AACR Annual Meeting 2008 Conference